Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac to Perform the Analytic Phase of AclarusDx™ for Exonhit

Published: Tuesday, July 05, 2011
Last Updated: Tuesday, July 05, 2011
Bookmark and Share
Exonhit AclarusDx™ is a micro-array-based test intended to aid in the diagnosis of AD by detecting biomarkers specific for AD in peripheral blood.

Almac’s Diagnostics business unit has announced that it will be the central service lab to perform the analytic phase and deliver to the clinicians the result of Exonhit AclarusDx™ diagnostic test.

Exonhit AclarusDx™ is a micro-array-based test intended to aid in the diagnosis of Alzheimer’s disease (AD) by detecting biomarkers specific for AD in peripheral blood.

The test was CE marked in March 2011 and has now been introduced for clinical diagnostic use in France. The test will be performed by Almac from its ISO17025 accredited laboratory. Almac will deliver the AclarusDx™ result to the clinicians.

Almac recently announced the opening of its CLIA registered Clinical Testing laboratory from which it is currently delivering the Therascreen® K-RAS Mutation Test. AclarusDx™ will be the second commercial clinical test that will be managed by Almac.

In addition to standard molecular tests Almac will deliver a range of novel, validated biomarker assays from its Clinical Testing Laboratory to facilitate the stratification and enrichment of prospective clinical trials.

Professor Paul Harkin, President and Managing Director of Almac’s Diagnostics business said: “The partnership with Exonhit is an excellent arrangement for both companies. Exonhit will focus on the sales and marketing of AclarusDx while we will focus on the delivery of the diagnostic in our ISO17025 certified laboratory.”

Loïc Maurel, M.D., Chairman of the Management Board at Exonhit said: “We chose Almac Diagnostics as our reference lab to perform the analytic phase of AclarusDx™ due to its strong expertise in molecular biology and its practice of the Affymetrix platform. We also view the location of Almac Diagnostics in Northern Ireland as an asset for the upcoming roll-out of AclarusDx™ in Europe.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gene Expression Study to Develop Prognostic Test for Early Non-Small Cell Lung Cancer
Almac Diagnostics has announced details of a global multi-centre collaborative lung cancer study with leading research organisations in the USA, Canada, Asia and Europe.
Thursday, September 04, 2008
Almac Wins Top Award at Tech Idol Showcase
Almac’s DSA™ research tool was judged to be the best new technology at the 2007 ‘Discovery 2 Diagnostics’ conference in Pennsylvania.
Monday, December 24, 2007
Almac Diagnostics Announces Pioneering Genetic Research on Ductal Carcinoma in Situ
Almac is undertaking a collaborative study with Oxford University to create a gene signature to predict the recurrence of ductal carcinoma in situ.
Thursday, August 09, 2007
Scientific News
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Adipose Analysis on Microfluidic Chips
Scientists have developed a microfluidic chip the works with minute liquid quantities to grow and study cells.
New Device can Study Electric Field Cancer Therapy
Microfluidic device allows study of electric field cancer therapy through low-intensity fields, preventing malignant cells spreading.
DNA Production Facility Begins Operation
Scientists mark the opening of the UK's first fully automated DNA construction and modification facility.
A “Micro Winery” That Makes Wine Continuously
An American professor, working in collaboration with EPFL, is developing a miniature device for producing wine non-stop and testing different fermentation processes.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!